How long can an elderly person live with AML?
How long can an elderly person live with AML?
End-of-life care is of particular concern for elderly patients with AML because prognosis is poor and has not changed in several decades. Median survival for patients 65 or older is roughly two months and drops to as low as one month for patients over 85 years.
Which AML has worst prognosis?
Secondary AML has a worse prognosis, as does treatment-related AML arising after chemotherapy for another previous malignancy. Both of these entities are associated with a high rate of unfavorable genetic mutations.
How long do you live with acute myeloid leukemia?
Generally with AML, around 20 out of 100 people (around 20%) will survive their leukaemia for 5 years or more after their diagnosis.
When to screen for mutkit in AML patients?
We also confirm the adverse impact of mutKIT on relapse risk in t (8;21) AML. We suggest that patients with core-binding factor AML should be screened for mutKIT at diagnosis for both prognostic and therapeutic purposes, given that activated KIT potentially can be targeted with novel tyrosine kinase inhibitors.
When to test for activated kit in AML?
We suggest that patients with core-binding factor AML should be screened for mutKIT at diagnosis for both prognostic and therapeutic purposes, given that activated KIT potentially can be targeted with novel tyrosine kinase inhibitors. Trial registration: ClinicalTrials.gov NCT00233454 .
What is the remission rate for mutkit patients?
Among patients with t (8;21), 22% had mutKIT (18% with mutKIT17 and 4% with sole mutKIT8). Complete remission rates of patients with mutKIT and wild-type KIT (wtKIT) were similar in both cytogenetic groups.
What is the prognostic significance of KIT mutations?
In t (8;21), mutKIT predicted higher CIR (P = .017; 5-year CIR, 70% v 36%), but did not influence OS. Conclusion: We report for the first time that mutKIT, and particularly mutKIT17, confer higher relapse risk, and both mutKIT17 and mutKIT8 appear to adversely affect OS in AML with inv (16).